Related Experiment Video
Updated: Jun 20, 2025
10:25
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
4.6K
Protective non-neutralizing SARS-CoV-2 monoclonal antibodies
Arman Izadi1, Pontus Nordenfelt2
1Department of Clinical Sciences Lund, Division of Infection Medicine, Faculty of Medicine, Lund University, Lund, Sweden; Karolinska University Hospital, Stockholm, Sweden.
Trends in Immunology
|July 21, 2024
Summary
Non-neutralizing antibodies, including monoclonal antibodies (mAbs), offer robust protection against SARS-CoV-2 by engaging Fc-mediated functions. Enhancing these functions via antibody engineering shows promise for durable treatments less susceptible to viral mutations.
Area of Science:
- Immunology and Virology
- Antibody Therapeutics
Background:
- Recent research highlights the protective role of non-neutralizing anti-spike antibodies against SARS-CoV-2.
- These antibodies, particularly monoclonal antibodies (mAbs), leverage Fc-mediated functions like complement activation and cellular cytotoxicity for protection.
Purpose of the Study:
- To discuss the evidence supporting non-neutralizing mAb-mediated protection against SARS-CoV-2 infection.
- To explore strategies for enhancing Fc-mediated functions of non-neutralizing mAbs through antibody engineering.
- To identify key unanswered questions regarding the characteristics, risks, and mechanisms of protective non-neutralizing mAbs.
Main Methods:
- Review of existing studies on non-neutralizing antibody functions and protection against SARS-CoV-2.
- Discussion of antibody engineering techniques aimed at enhancing Fc-mediated effector functions.
- Identification of critical research gaps and future directions for studying these antibodies.
Main Results:
- Non-neutralizing mAbs demonstrate significant potential in conferring protection against SARS-CoV-2.
- Fc-mediated functions are crucial for the protective capacity of these antibodies.
- Conserved epitopes on non-neutralizing mAbs may offer greater resistance to viral mutations compared to neutralizing mAbs.
Conclusions:
- Non-neutralizing mAbs represent a promising avenue for durable antibody treatments against SARS-CoV-2.
- Further research is needed to fully understand their protective mechanisms, optimize their engineering, and assess potential risks.
- Investigating protective non-neutralizing mAb characteristics, appropriate study models, and durability is essential.
